☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Amylyx
Amylyx Reports the Completion of Patient Enrollment in P-III Trial (PHOENIX) of AMX0035 for Amyotrophic Lateral Sclerosis
February 3, 2023
Amylyx’s Relyvrio (sodium phenylbutyrate and taurursodiol) Receives the US FDA’s Approval for the Treatment of ALS
September 30, 2022
Amylyx Publishes Results of AMX0035 in P-II (CENTAUR) Trial for the Treatment of Amyotrophic Lateral Sclerosis in Muscle & Nerve
May 6, 2022
Amylyx Reports Submission of MAA to EMA for AMX0035 to Treat ALS
January 5, 2022
Amylyx Reports US FDA Acceptance of NDA and Priority Review for AMX0035 to Treat ALS
December 30, 2021
PharmaShots Weekly Snapshots (November 01, 03, 2021)
November 5, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.